News
PPBT
2.205
-0.45%
-0.010
Purple Biotech Unveils Strategic Advancements in Oncology Therapies
TipRanks · 3d ago
Weekly Report: what happened at PPBT last week (0428-0502)?
Weekly Report · 5d ago
Purple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic Cancer
TipRanks · 04/30 11:30
Purple Biotech announces significant efficacy results from Phase 2 CM24 study
TipRanks · 04/30 11:16
Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study
Benzinga · 04/30 11:08
PURPLE BIOTECH REPORTS FINAL DATA FROM PHASE 2 STUDY OF CM24 IN PANCREATIC CANCER PATIENTS AT AACR 2025 ANNUAL MEETING: IMPROVED OUTCOMES AND SIGNIFICANT EFFICACY IN BIOMARKER-ENRICHED SUBGROUPS
Reuters · 04/30 11:00
Purple Biotech Announces Promising NT219 Data for Cancer Treatment
TipRanks · 04/28 13:44
Purple Biotech reports NT219 data at AACR meeting
TipRanks · 04/28 12:38
Purple Biotech Reports Data At AACR For Colorectal And Head And Neck Cancer
Benzinga · 04/28 12:29
Weekly Report: what happened at PPBT last week (0421-0425)?
Weekly Report · 04/28 09:44
Purple Biotech Announces Key Decisions from April 2025 Shareholder Meeting
TipRanks · 04/22 20:57
Weekly Report: what happened at PPBT last week (0414-0418)?
Weekly Report · 04/21 09:44
Purple Biotech’s NT219 Shows Promise Against Colorectal Cancer Brain Metastasis
TipRanks · 04/16 11:28
Purple Biotech announces publication of study on potential of NT219
TipRanks · 04/16 11:13
Purple Biotech Reschedules Annual Shareholder Meeting Due to Lack of Quorum
TipRanks · 04/15 20:28
Weekly Report: what happened at PPBT last week (0407-0411)?
Weekly Report · 04/14 09:41
Weekly Report: what happened at PPBT last week (0331-0404)?
Weekly Report · 04/07 09:41
Purple Biotech to Join Oncology Conference Panel Discussion
TipRanks · 04/01 11:27
Weekly Report: what happened at PPBT last week (0324-0328)?
Weekly Report · 03/31 09:44
Purple Biotech to Present at 2025 AACR Meeting
TipRanks · 03/28 12:32
More
Webull provides a variety of real-time PPBT stock news. You can receive the latest news about Purple Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PPBT
More
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Recently
Symbol
Price
%Change
    ZG
  • 66.78
  • +0.04%